Karyopharm Therapeutics Inc (NASDAQ:KPTI) EVP Christopher Brett Primiano sold 1,500 shares of the business’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $13.00, for a total value of $19,500.00. Following the transaction, the executive vice president now directly owns 9,881 shares in the company, valued at $128,453. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Christopher Brett Primiano also recently made the following trade(s):
- On Tuesday, December 12th, Christopher Brett Primiano sold 27,042 shares of Karyopharm Therapeutics stock. The stock was sold at an average price of $10.28, for a total value of $277,991.76.
Karyopharm Therapeutics Inc (NASDAQ KPTI) traded up $0.57 on Thursday, reaching $13.68. The company had a trading volume of 361,944 shares, compared to its average volume of 214,976. The company has a market cap of $618.67, a P/E ratio of -4.95 and a beta of 4.11. Karyopharm Therapeutics Inc has a twelve month low of $7.48 and a twelve month high of $14.63.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN lifted its position in shares of Karyopharm Therapeutics by 18.8% during the 4th quarter. Wells Fargo & Company MN now owns 30,974 shares of the company’s stock valued at $298,000 after acquiring an additional 4,902 shares during the period. Teacher Retirement System of Texas bought a new stake in shares of Karyopharm Therapeutics during the 4th quarter valued at $115,000. Schwab Charles Investment Management Inc. lifted its position in shares of Karyopharm Therapeutics by 7.1% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 150,289 shares of the company’s stock valued at $1,443,000 after acquiring an additional 9,929 shares during the period. Iguana Healthcare Management LLC lifted its position in shares of Karyopharm Therapeutics by 33.3% during the 3rd quarter. Iguana Healthcare Management LLC now owns 400,000 shares of the company’s stock valued at $4,392,000 after acquiring an additional 100,000 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in shares of Karyopharm Therapeutics by 753.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 307,200 shares of the company’s stock valued at $3,342,000 after acquiring an additional 271,208 shares during the period. Institutional investors and hedge funds own 58.02% of the company’s stock.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.